Kairos Pharma (KAPA) Shares Outstanding (2023 - 2025)
Kairos Pharma's (KAPA) quarterly Shares Outstanding (Entity) came in at $20.8 million in Q4 2025, up 83.34% YoY from $11.4 million in Q4 2024, and up 17.34% on a QoQ basis from $17.7 million in Q2 2025.
Kairos Pharma (KAPA) Shares Outstanding (2023 - 2025) Analysis & Trends
Kairos Pharma (KAPA) has 3 years of Shares Outstanding (Entity) data on file, last reported at $20.8 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) rose 83.34% year-over-year to $20.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.8 million (up 83.34% YoY) and the FY2025 annual result came in at $20.8 million, up 83.34% from the prior year.
- Shares Outstanding (Entity) grew to $20.8 million in Q4 2025, from $17.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $20.8 million in Q4 2025 to a low of $10.3 million in Q3 2023.
- A 3-year average of $13.4 million and a median of $11.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) grew 7.52% — and 2025, when it jumped 83.34%.
- Tracing KAPA's Shares Outstanding (Entity) over 3 years: stood at $10.6 million in 2023, then gained by 7.52% to $11.4 million in 2024, then jumped by 83.34% to $20.8 million in 2025.
- The last three Shares Outstanding (Entity) figures came in at $20.8 million (Q4 2025), $17.7 million (Q2 2025), and $15.8 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Kairos Pharma | 5.39 Mn | 55,970.58 | - | 18.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 18.43 Mn |
| Jun 30, 2025 | 17.21 Mn |
| Mar 31, 2025 | 15.88 Mn |
| Dec 31, 2024 | 11.36 Mn |
| Sep 30, 2024 | 10.91 Mn |
| Jun 30, 2024 | 10.56 Mn |
| Mar 31, 2024 | 10.56 Mn |
| Dec 31, 2023 | 10.38 Mn |
| Sep 30, 2023 | 10.33 Mn |